Proteine Resources
We're on a mission to revolutionize the use of insects, maximizing their potential in various industries. Our flagship product is a premium insect protein boasting 64% protein content in dry mass. What sets it apart are its remarkable medical properties, including unique amino and fatty acid profiles, as well as a rich array of vitamins and macro- and micronutrients. Even more impressive is its production efficiency — it can be produced 50% cheaper and at a larger scale, far outpacing any competition in the market. Our product range caters to the poultry feed, pet food, and veterinary supplement industries. These products are integral components of animal feeds, significantly reducing mortality rates, enhancing health, appearance, and overall well-being. Now, imagine the possibilities if we harness the bioactive compounds found in insects such as serotonin, melatonin, ecdysone, lovastatin, GABA, phenolic compounds, cordycepin, erinacenes, hericenones, psilocybin, psilocin, beta-glucan, and triterpenes. With these potent ingredients, we can develop high-value cosmetics and medicines tailored for specific therapeutic purposes, boasting exceptional bioavailability. This is the future of innovation in healthcare and beauty.
We're on a mission to revolutionize the use of insects, maximizing their potential in various industries. Our flagship product is a premium insect protein boasting 64% protein content in dry mass. What sets it apart are its remarkable medical properties, including unique amino and fatty acid profiles, as well as a rich array of vitamins and macro- and micronutrients. Even more impressive is its production efficiency — it can be produced 50% cheaper and at a larger scale, far outpacing any competition in the market. Our product range caters to the poultry feed, pet food, and veterinary supplement industries. These products are integral components of animal feeds, significantly reducing mortality rates, enhancing health, appearance, and overall well-being. Now, imagine the possibilities if we harness the bioactive compounds found in insects such as serotonin, melatonin, ecdysone, lovastatin, GABA, phenolic compounds, cordycepin, erinacenes, hericenones, psilocybin, psilocin, beta-glucan, and triterpenes. With these potent ingredients, we can develop high-value cosmetics and medicines tailored for specific therapeutic purposes, boasting exceptional bioavailability. This is the future of innovation in healthcare and beauty.
Proteine Resources has raised $1.5M across 3 rounds. Its most recent round was a Venture - Series Unknown in Nov 2025. Full funding history, investors, and team are detailed below.
Funding history
3 rounds on record — latest round shown, the rest unlock with a paid plan.
Unlock 2 earlier rounds — dates, amounts, round types — plus the lead investor for every round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
Proteine Resources is featured in
Similar companies
Quantum was created to develop solutions that address specific difficulties in cardiac surgery, cardiology, and respiratory medicine.
Ryvu is a biopharmaceutical company that is creating small-molecule treatments to overcome the challenges of current oncology therapies.
BioCam designs and manufactures an endoscopic capsule for imaging of the digestive system along with AI-powered software for automatic detection and real-time determination of potential threats. The company's goal is to reduce the cost of gastrointestinal examinations, increase patient comfort, and popularization of capsule endoscopy.
Orthoget is a progressive company specializing in bioengineering that has been engaged in research and innovation related to intramedullary implants for long bones.
Beeline Medicines is a biotechnology company that identifies and provides precise treatments to autoimmune inflammatory disorders.
Tenon Medical, a biotech firm specializing in enhancing surgical solutions for the SI joint, was established in 2012 in Morgan Hill, California.
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other therapeutic areas with a commercial platform and four marketed products in the US. Midatech's strategy is to develop products in-house in oncology and with partners in other indications, and to accelerate growth organically and through strategic acquisitions.
CollPlant is a regenerative medicine company that focuses on 3D bioprinting of tissues and organs and also develops and commercializes tissue repair products for orthobiologics. The company's products are based on the rhCollagen that is produced with CollPlant’s proprietary plant-based genetic engineering technology. The rhCollagen BioInk is ideal for 3D bioprinting of tissues and organs, and the unique Vergenix line of rhCollagen products contains a soft tissue repair matrix for treating tendinopathy and a wound repair matrix to promote rapid optimal healing of acute and chronic wounds. CollPlant is headquartered in Rehovot, Israel.
iPremom is a healthcare technology company that develops molecular diagnostic solutions for the early detection and prediction of pregnancy complications, particularly preeclampsia.
Aptevo Therapeutics is a biotech company based in Seattle that focuses on developing new treatments for cancer and blood disorders. They use a special technology called ADAPTIR™ to improve outcomes for cancer patients. The company is known for its supportive work environment, culture of innovation, and unique platform technology. As a result, Aptevo has been able to attract talented individuals with experience in other leading biotech companies such as Trubion, ZymoGenetics, Immunex, Dendreon, and VLST.
Oblique Therapeutics is developing a new type of antibody-based medication for chronic pain and metastatic cancer. Oblique Therapeutics is an early stage innovation-driven pharmaceutical company aiming at developing transformative medicines against advanced and metastatic cancer.
Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer. The company has engaged in deep analyses of tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and of tumor cell signaling pathways within cold tumors, providing laboratories with development of novel antibody-based immunotherapies. It was founded in 2019 and is based in Boston, Massachusetts.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.